☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC September Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Testosterone 24 hours transdermal patch (Intrinsa®) has been rejected for the treatment of hypoactive sexual desire disorder (HSDD) in surgically induced menopausal women

Pioglitazone (Actos®) has been accepted for use in combination with insulin in type 2 diabetes mellitus patients.

Celecoxib (Celebrex®) has been rejected for use in ankylosing spondylitis. This rejection was made because the manufacturer failed to submit a New Product Assessment Form as required by the SMC evaluation process.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC September Update' by emailShare 'SMC September Update' on FacebookShare 'SMC September Update' on TwitterShare 'SMC September Update' on LinkedInShare 'SMC September Update' on reddit


No Comments to “SMC September Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.